VKTX Share Price Performance
US$33.67
6.18 (22.48%)
63.7% undervalued intrinsic discount
US$92.72
Fair Value
Price US$33.67
AnalystConsensusTarget US$92.72
AnalystHighTarget US$125.00
Fair ValueUS$92.72
Share Pricen/a
Seeking Alpha • Aug 07
Viking Therapeutics, Inc. Stock Price
- 2 Narratives written by author
- 1 Comments on narratives written by author
- 183 Fair Values set on narratives written by author
VKTX Community Narratives
AN
Fair Value
·Fair Value US$92.72 63.7% undervalued intrinsic discount
Obesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis
0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
AN
Fair Value
·Fair Value US$125 73.1% undervalued intrinsic discount
Obesity Pipeline And Phase III Milestones Will Transform This Cardiometabolic Pure Play
1users have liked this narrative
1users have commented on this narrative
3users have followed this narrative
Viking Therapeutics
73.1% undervalued intrinsic discount
Obesity Pipeline And Phase III Milestones Will Transform This Cardiometabolic Pure Play
View narrativeAN
Published 19 Mar
Viking Therapeutics
63.7% undervalued intrinsic discount
Obesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis
View narrativeAN
Published 5 Mar
Trending Discussion
AL
Update plz
0
|0
Recently Updated Narratives
AN
Obesity Pipeline And Phase III Milestones Will Transform This Cardiometabolic Pure Play
Fair Value: US$125 73.1% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Obesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis
Fair Value: US$92.72 63.7% undervalued intrinsic discount
15 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Viking Therapeutics, Inc. Key Details
About VKTX
- Founded
- 2012
- Employees
- 65
- CEO
- WebsiteView website
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
